Gary McLean is an Honorary Research Fellow in the Airway Disease Infection Section of the National Heart and Lung Institute.
His prior research on blood cell development, immune responses to human viral pathogens and molecular studies of antibody generation were performed in North America.
Currently his research investigates immune responses to rhinovirus infections and the role of microvesicles in the spread of respiratory viral infections - the aim of his research is to generate novel therapeutic interventions or a protective vaccine to rhinovirus.
et al., 2020, A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection., Eur J Pharm Sci, Vol:153
et al., 2020, An investigation of rhinovirus infection on cellular uptake of poly (glycerol-adipate) nanoparticles., Int J Pharm, Vol:589
McLean GR, 2019, Vaccine strategies to induce broadly protective immunity to rhinoviruses, Human Vaccines & Immunotherapeutics, Vol:16, ISSN:2164-5515, Pages:684-686
et al., 2019, Epitope mapping of antibodies induced with a conserved rhinovirus protein generating protective anti-rhinovirus immunity, Vaccine, Vol:37, ISSN:0264-410X, Pages:2805-2813